Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Eli Lilly and Company
Quetzal Therapeutics
Orca Biosystems, Inc.
Taiho Oncology, Inc.
Celgene
Cellectar Biosciences, Inc.
Takeda
Eli Lilly and Company
Ossium Health, Inc.
Eli Lilly and Company
Eli Lilly and Company
Constellation Pharmaceuticals
Cogent Biosciences, Inc.
Novartis
Eli Lilly and Company
Eli Lilly and Company
Celularity Incorporated
Beckman Coulter, Inc.
Vincerx Pharma, Inc.
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
AO GENERIUM
Amgen
Takeda
Takeda
Pfizer
Novartis
Sunesis Pharmaceuticals
Bellicum Pharmaceuticals
Gilead Sciences
Acrotech Biopharma Inc.
Celgene
Il-Yang Pharm. Co., Ltd.
Sunesis Pharmaceuticals
Sunesis Pharmaceuticals
Seagen Inc.
Il-Yang Pharm. Co., Ltd.
Seagen Inc.
Seagen Inc.
Seagen Inc.
Ariad Pharmaceuticals
Senesco Technologies, Inc.
Kiadis Pharma
Chroma Therapeutics
Seagen Inc.
Infinity Pharmaceuticals, Inc.